What is KRYS's current stock price?

KRYS (Krystal Biotech, Inc.) is currently trading at $299.45 with a market cap of $8.83B.

What sector is Krystal Biotech, Inc. in?

Krystal Biotech, Inc. (KRYS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is KRYS a good stock to buy?

Analysts have a Buy consensus on KRYS with a price target of $326.20. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

KRYS Krystal Biotech, Inc.

Healthcare

$299.45-1.57%ClosedMarket Cap: $8.83B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

36.96

PEG

0.28

P/B

6.87

P/S

21.15

EV/EBITDA

44.91

DCF Value

$546.96

FCF Yield

2.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

92.8%

Operating Margin

42.8%

Net Margin

53.9%

ROE

19.3%

ROA

16.1%

ROIC

13.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$116.4M	$55.9M	$—
Q4 null	$107.1M	$51.4M	$—
FY null	$389.1M	$204.8M	$—
Q3 null	$97.8M	$79.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$326.20

Target (Median)

$323.00

Target Range

$300.00 - $371.00

0 Strong Buy10 Buy1 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-22

CitigroupBuy

2026-05-05

Evercore ISI GroupOutperform

2026-05-05

GuggenheimBuy

2026-02-25

Chardan CapitalBuy

2026-02-18

Trading Activity

Insider Trades

View All

Thomas John Charlesofficer: EVP, General Counsel

SellFri Mar 06

Thomas John Charlesofficer: EVP, General Counsel

SellFri Mar 06

Goux Laurent Louis Jeanofficer: EVP, Head of International

SellFri Mar 06

Goux Laurent Louis Jeanofficer: EVP, Head of International

SellFri Mar 06

Goux Laurent Louis Jeanofficer: EVP, Head of International

SellFri Mar 06

Related AI Research

8-K EventMay 4, 2026

KRYS files 8-K — Item 2.02 Results of Operations

Krystal Biotech, Inc.

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.49

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Peers

TFX